MA43709A - Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations - Google Patents

Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Info

Publication number
MA43709A
MA43709A MA043709A MA43709A MA43709A MA 43709 A MA43709 A MA 43709A MA 043709 A MA043709 A MA 043709A MA 43709 A MA43709 A MA 43709A MA 43709 A MA43709 A MA 43709A
Authority
MA
Morocco
Prior art keywords
empagliflozin
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA043709A
Other languages
English (en)
Inventor
Uli Broedl
Afshin Salsali
Hans-Juergen Woerle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA43709A publication Critical patent/MA43709A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043709A 2016-03-16 2017-03-13 Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations MA43709A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309008P 2016-03-16 2016-03-16
US201662420062P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MA43709A true MA43709A (fr) 2018-11-28

Family

ID=58267120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043709A MA43709A (fr) 2016-03-16 2017-03-13 Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Country Status (13)

Country Link
US (5) US20170266152A1 (fr)
EP (1) EP3429595A1 (fr)
JP (4) JP7161405B2 (fr)
KR (4) KR20230028568A (fr)
CN (1) CN109069525A (fr)
AU (2) AU2017233889B2 (fr)
BR (1) BR112018016001A2 (fr)
CA (1) CA3017992A1 (fr)
CL (1) CL2018002532A1 (fr)
MA (1) MA43709A (fr)
MX (3) MX2018011088A (fr)
PH (1) PH12018501969A1 (fr)
WO (1) WO2017157816A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
WO2019069230A1 (fr) * 2017-10-02 2019-04-11 Poxel Méthodes de traitement d'une insuffisance cardiaque avec fraction d'éjection préservée
EP3806828A1 (fr) 2018-06-14 2021-04-21 Poxel Comprimé pelliculé comprenant un dérivé de triazine destiné à être utilisé dans le traitement du diabète
CA3105626A1 (fr) * 2018-07-19 2020-01-23 Astrazeneca Ab Methodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
CN114286682A (zh) * 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
IT201900006624A1 (it) * 2019-05-08 2020-11-08 Moret Giannino Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
BR112020008705A2 (pt) 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
JPWO2021049612A1 (fr) * 2019-09-13 2021-03-18
AU2021222297A1 (en) 2020-02-17 2022-08-04 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
WO2023006718A1 (fr) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez des mammifères non humains à l'exclusion de félins, en particulier des canidés
JP7396579B2 (ja) 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
EP2483286B1 (fr) * 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Procédé de préparation d'une forme cristalline de 1-chloro-4-( -d-glucopyranos-1-yl)-2-[4-((s)-tétrahydrofuran-3-yloxy)-benzyl]-benzène
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) * 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
EA033286B1 (ru) * 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек

Also Published As

Publication number Publication date
JP2023001136A (ja) 2023-01-04
AU2022246392A1 (en) 2022-10-27
PH12018501969A1 (en) 2019-06-17
KR20230028565A (ko) 2023-02-28
CA3017992A1 (fr) 2017-09-21
JP2019508453A (ja) 2019-03-28
JP7454531B2 (ja) 2024-03-22
US20220211659A1 (en) 2022-07-07
KR20180122004A (ko) 2018-11-09
WO2017157816A1 (fr) 2017-09-21
US20210059974A1 (en) 2021-03-04
CL2018002532A1 (es) 2019-01-04
KR20230111262A (ko) 2023-07-25
EP3429595A1 (fr) 2019-01-23
US20180318251A1 (en) 2018-11-08
BR112018016001A2 (pt) 2018-12-18
CN109069525A (zh) 2018-12-21
MX2022008491A (es) 2022-08-02
JP2021181461A (ja) 2021-11-25
AU2017233889A1 (en) 2018-08-09
AU2017233889B2 (en) 2022-07-07
US20170266152A1 (en) 2017-09-21
JP7161405B2 (ja) 2022-10-26
JP2024083347A (ja) 2024-06-21
MX2018011088A (es) 2018-11-22
MX2021010329A (es) 2021-10-13
US20190350894A1 (en) 2019-11-21
KR20230028568A (ko) 2023-02-28

Similar Documents

Publication Publication Date Title
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA50753A (fr) Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA46742A (fr) Composition pharmaceutique, méthodes de traitement et leurs utilisations
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA43361A (fr) Composition pour le soin et la protection de cultures
MA47459A (fr) Anticorps anti-tryptase, compositions les contenant et leurs utilisations
MA43556A (fr) Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci
MA40427A (fr) Composition comprenant des substances naturelles et/ou des extraits
MA47516A (fr) Composition pharmaceutique
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation